Robert Lyne, Chief Executive Officer, PureTech • Photo Credit: PureTech

BOSTON, December 18, 2025 (WELLNESS INTERVIEWS) — Biotherapeutics company PureTech Health has announced the appointment of Robert Lyne as Chief Executive Officer and member of the Board of Directors.

Wellness Interviews

♾️

Wellness Interviews ♾️

Lyne, who has served as Interim CEO since July 2025, joined the company in January 2024 as Chief Portfolio Officer.

"I'm honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I’ve seen first-hand the strength of our programs, the talent of our team, and the power of our differentiated model. I’m keen to build on this foundation, working closely with the Board to drive the next phase of execution as we advance transformative therapies for patients and deliver long-term value for our shareholders. Our immediate focus is on securing the funding needed to advance our newest Founded Entity, Celea Therapeutics, following the successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration. This process is progressing, and we expect to close within the first half of 2026, after which PureTech’s operational run rate will reduce significantly. In parallel, we are also actively pursuing financing in 2026 for Gallop Oncology, as the strong initial topline data continue to mature, and the program advances to the next stage of development. Going forward, we intend to operate with a streamlined structure and significantly reduced overhead. This will be combined with a disciplined investment posture, pursuing focused innovation initiatives that can be advanced to key inflection points with relatively modest spend to improve our return on capital. Once Celea is fully financed, we expect to evaluate the most effective means of delivering value to shareholders, including potential capital returns, as part of an integrated strategy that continues targeted and impactful innovation. In the meantime, our priority is preserving capital, maintaining flexibility, and positioning PureTech for value creation," said Lyne.

According to Sharon Barber-Lui, Interim Chair of PureTech’s Board of Directors, Lyne’s leadership strengthens the company’s direction.

“We are pleased to appoint Rob as PureTech’s CEO. As Interim CEO, Rob has demonstrated strong leadership, strategic clarity, and a deep understanding of the business and key stakeholders. Rob’s appointment positions the Company to execute against a clear plan to sharpen strategic and operational focus and optimize shareholder returns. The Board supports Rob’s disciplined approach to maintaining a lean operating model whilst concentrating on capital-efficient innovation to maximize shareholder value. The Board is confident that Rob is the right person to lead PureTech forward,” said Barber-Lui.

Lyne previously served as CEO of Arix Bioscience plc and has held senior roles across UK-listed life science companies. His experience includes more than a decade of leadership in venture financing, portfolio strategy, and governance.

For more information, visit www.puretechhealth.com.

Source: PureTech Health